Arlington Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Arlington Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-34	Closed	-$11.8K	–	395
2023 Q3	$11.8K	Hold	34	–	–	﹤0.01%	220
2023 Q2	$12K	Sell	34 -66	-66%	-$22.2K	﹤0.01%	447
2023 Q1	$31.5K	Buy	+100	New	+$30K	﹤0.01%	299
2022 Q1	–	Sell	-49	Closed	-$11K	–	658
2021 Q4	$11K	Buy	+49	New	+$9.53K	﹤0.01%	461
2020 Q2	–	Sell	-46	Closed	-$11K	–	289
2020 Q1	$11K	Hold	46	–	–	0.01%	163
2019 Q4	$10K	Buy	+46	New	+$9.31K	0.01%	197
2019 Q1	–	Sell	-46	Closed	-$8K	–	240
2018 Q4	$8K	Buy	+46	New	+$7.97K	0.01%	174

Other funds holding VRTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Arlington Partners's VRTX Position: Q4 2023 in Review

Arlington Partners sold out of Vertex Pharmaceuticals (VRTX) in Q4 2023, closing a stake of 34 shares — an estimated $11.8K sold.

Arlington Partners first reported a position in VRTX in Q4 2018 and held it in 7 quarters. The position peaked at $31.5K in Q1 2023. 1,439 funds tracked by Wall St. Rank hold VRTX as of Q4 2023.

Arlington Partners reported no remaining Vertex Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Arlington Partners sold 34 Vertex Pharmaceuticals shares in Q4 2023, an estimated $11.8K.
Arlington Partners first reported a position in Vertex Pharmaceuticals in Q4 2018 and held it in 7 quarters.
Arlington Partners's Vertex Pharmaceuticals position peaked at $31.5K in Q1 2023.
1,439 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2023.

Based on Arlington Partners's 13F filing for Q4 2023, filed 24 Jan 2024.